Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in…
Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...
Read More...
